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The aim of this study was to investigate the protective effect of chlorogenic acid (CA) on liver injury
caused by bile duct ligation (BDL), as well as the potential mechanism. Permanent bile duct ligation
induced liver injury was evaluated by liver index, liver function and pathological observation. Oral
administration of CA for 3 weeks markedly attenuated liver swelling and ﬁbrosis. Blood biochemistry
results revealed that CA decreased alanine transaminase, aspartate aminotransferase, alkaline phos-
phatase, total bilirubin, direct bilirubin and total bile acid. PCR analysis indicated that collagen I, collagen
III, transforming growth factor and vascular endothelial growth factor mRNAwere increased markedly by
BDL treatment but these increases were suppressed by CA. Additionally, CA effectively alleviated the
expression of a-smooth muscle actin induced by BDL. Taken together, our data indicate that CA can
efﬁciently inhibit BDL-induced liver injury in rats, which is a candidate drug for preventing liver injury
against cholestasis.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Cholestasis is a clinical syndrome including obstructive and
metabolic type. Obstructive cholestasis is a mechanical blockage in
the duct system that can occur from a gallstone or malignancy, and
metabolic types of cholestasis which are disturbances in bile for-
mation that can occur because of genetic defects or acquired as a
side effect of many medications. Intrahepatic accumulation of
cytotoxicbile acids can directly induce hepatocytes apoptosis (1),
which may eventually lead to ﬁbrosis and cirrhosis (2e4). The
pathogenesis of liver ﬁbrosis is characterized by excessive extra-
cellular matrix deposition and is based on complex interactions
between an abundance of liver-resident cells andmatrix-producing
hepatic stellate cells (HSCs). The activated hepatic stellate cells can
up-regulate pro-ﬁbrogenic cytokines such as TGF-b1 and VEGF. The
mechanism of hepatocyte apoptosis triggers HSCs activation is not
clear, either directly by phagocytosis of the apoptotic bodies (5), or
indirectly by damage-associated molecular patterns inducing the
migration or activation of HSCs (6). Thus effective treatment ap-
proaches for liver ﬁbrosis may include drugs that target HSCs
activation, hepatocyte apoptosis, or both.4.
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d/4.0/).Chlorogenic acid (CA), an ester of quinic acid and caffeic acid, is a
major active ingredient found in many traditional Chinese herbs and
herbal medicine (7). It exerts a broad spectrum of pharmacological
activities including anti-hypertension (8), anti-inﬂammation (9,10),
antioxidantion (11), antitumor (12) as well as inhibiting histamine
production in the epidermis (13). Increasing studies show that
chlorogenic acid presents remarkable hepatoprotective effects on
different liver injury models. For example, chlorogenic acid can
efﬁciently inhibit CCl4-induced liver ﬁbrosis in rats (14) and protect
against acute hepatotoxicity induced by lipopolysaccharide in mice
(15). A recent study showed that chlorogenic acid exerts therapeutic
detoxiﬁcation against acetaminophen-induced liver injury in mice
(16). Surgical bile duct ligation is a well-established model that can
induce obstructive jaundice (17). Moreover, it is an acceptable model
to evaluate the potential hepatoprotective effect of some candidate
drugs (18). In this study, we investigated the potential protective
effects of chlorogenic acid and anti-ﬁbrotic activity on hepatic
damage rats induced by common bile duct ligation.
2. Materials and methods
2.1. Drugs
Chlorogenic acid (purity >95% tested by titration) was pur-
chased from SigmaeAldrich (St Louis, MO, USA). CA was dissolved
in distilled water and administrated i.g. at a volume of 10 ml/kg.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Table 1
Primer sequences for PCR ampliﬁcation.
mRNA Primer sequence
Collagen I FP: 50-CAGAGTGGAAGAGCGATTA-30
RP: 50-CAAGGACAGTGTAGGTGAA-30






GAPDH FP: 50-TCTCCTGCGACTTCAACA -30
RP: 50-TGTAGCCGTATTCATTGTCA-30
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Adult male SpragueeDawley rats, weighing 220e250 g, were
purchased from Institute of Laboratory Animal Science, Chinese
Academy of Medical Sciences (Beijing, China). The rats were
maintained in a controlled environment at 22 ± 2 C and 55 ± 5%
relative humidity under a 12-h dark/light cycle and were acclima-
tized for at least 1 week prior to use. All experimental procedures
were approved by the Animal Care and Use Committee of Hainan
General Hospital (Haikou, China).
2.3. Surgical procedure
Rats were fasted for 12 h with water ad libitum before the
operation. Each rat was weighed and anaesthetized with choral
hydrate (350mg/kg, i.p.). Following amidline incision, the common
bile duct was exposed and a double-ligature with 5e0 silk suture
was performed and the bile duct was sectioned between the liga-
tures. In the control-operated animals, the common bile duct was
freed from surrounding soft tissue without ligation. A two-layer
running suture was used for abdominal closure with 4e0 dexon
and 2e0 nylon. The operation was performed on a heating pad to
maintain body temperature at 37.5 ± 0.5 C, and the animal was
kept on the pad until recovery from anesthesia.
2.4. Experimental treatment
Rats subjected to bile duct ligationwere randomly divided into 5
groups containing 12 rats each (1): Rats in Group 1 were treated
with distilled water (2); Rats in Group 2 were treated with CA
37.5 mg/kg (3); Rats in Group 3 were treated with CA 75 mg/kg (4);
Rats in Group 4 were treated with CA 150 mg/kg (5); Rats in Group
5 were treated with Silibinin 150 mg/kg; The control-operated rats
treated with distilled water were served as Group 6. Daily oral
administration of CA, Silibinin or vehicle (distilled water) started on
day 1 post-surgery, and lasted for the termination of the experi-
ment on day 21.
2.5. Sample collection
The animals were anaesthetized and a second laparotomy was
performed. After blood samples were drawn from the inferior vena
cava, the liver was carefully dissected from its attachment and
totally excised. The blood samples were kept at 4 C for biochemical
analyses of alanine transaminase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), total bilirubin (TBIL), direct
bilirubin (DBIL), and total bile acid (TBA). The left lobe of the liver
was excised and ﬂushed with physiological saline and then cut into
two pieces, of which one piece was immediately frozen in liquid
nitrogen and stored at 80 C for western blotting and PCR, and
another was ﬁxed in 40 g/L paraformaldehyde for histological
analyses.
2.6. Blood biochemistry
After clotting, blood samples were centrifuged at 800 g for 5min
at 4 C. The top, clear layer was centrifuged again under the same
conditions to prepare serum. Alanine transaminase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin
(TBIL), direct bilirubin (DBIL), and total bile acid (TBA) were
measured using TBA-40FR automatic biochemistry analyzer
(TOSHIBA, Japan). The detailed procedures of measurements fol-
lowed the manufacture instruction in different reagent kits (Nanj-
ing Jiancheng Institute of Biological Engineering, China).2.7. Histopathological examination
A portion of liver in each group was ﬁxed in 10% formalin,
processed by routine histological procedures, embedded in
parafﬁn, and cut into 5-mm sections. The sections were stainedwith
hematoxylin and eosin (H&E) for histopathological examination
and with Masson's trichrome for assessment of ﬁbrosis. Sections
were examined in a blinded manner under a microscope (Leica TCS
SP, German). Each sample was observed at 100 magniﬁcation.
Fibrosis was graded according to the criteria (19) as follows:
grade 0, normal liver; grade 1, increase in collagen without septa
formation (small stellate expansions of the portal ﬁelds); grade 2,
formation of incomplete septa from the portal tract to the central
vein (septa that do not interconnect with each other); grade 3,
complete but thin septa interconnecting with each other so as to
divide parenchyma into separate fragments; and grade 4, the same
as grade 3, except for the presence of thick septa (complete
cirrhosis).
2.8. RNA isolation, cDNA synthesis, and reverse transcription-
polymerase chain reaction (PCR)
Samples (50 mg) of the liver tissue were ﬁrst cleaned with cold
physiological saline and then driedwith absorbent paper. Total RNA
for RT-PCR was isolated by lysing the tissue in 1 ml of Trizol (Gibco,
NY, USA). The RNAwas treated with 200 mL chloroform, centrifuged
(12,000 rpm,15min, 4 C), and precipitatedwith ethanol. Total RNA
(1 mg) from each liver samplewas subjected to reverse transcription
in a reaction volume of 10 mL using a Revert Aid™ First Strand cDNA
Synthesis Kit. Aliquots of the ﬁrst strand cDNAwere used to amplify
fragments speciﬁc to collagen I, collagen III, VEGF, TGF-b1 and
GAPDH by PCR using the primer pairs listed in Table 1. The iden-
tities of the resulting PCR products were conﬁrmed by sequence
analysis. PCR products were run on a 2% agarose gel stained with
ethidium bromide recorded on polaroid ﬁlm, and the bands
quantiﬁed by densitometry. The expression levels of all the tran-
scripts were normalized to that of GAPDHmRNA in the same tissue
samples.
2.9. Western blot analysis
Liver tissues stored at 80 C were homogenized on ice in ﬁve
volumes of the lysis buffer containing 50 mM TriseHCl (pH 7.5),
150 mM sodium chloride, 1% NP-40, 1 mM sodium orthovanadate,
1 mM sodium ﬂuoride, 2.5 mM sodium pyrophosphate, 1 mM b-
glycerol phosphate, 1 mM EDTA, 1 mM EGTA, 1 mg/ml leupeptin
and 1 mM PMSF. The lysate was centrifuged at 15,000 g for 10 min
at 4 C and the supernatant was used forWestern blot analysis of a-
SMA. Brieﬂy, samples were separated by a SDS-polyacrylamide gel
electrophoresis and then transferred onto PVDF membranes. The
membranes were blocked with 3% BSA in Tris-buffer saline. Then
D. Wu et al. / Journal of Pharmacological Sciences 129 (2015) 177e182 179the membranes were incubated at 4 C overnight with a-SMA
antibody (1:1000) and b-actin antibody (1:1000), respectively
(Santa Cruz Biotechnologies, Santa Cruz, CA). After washing, the
membranes were incubated with a horseradish peroxidase conju-
gated secondary antibody (mouse anti-rabbit IgG, 1:5000; rabbit
anti-goat IgG, 1:5000) (Santa Cruz Biotechnologies, Santa Cruz, CA)
for 1 h at room temperature and processed for visualization by
enzyme-linked chemiluminescence. Relative intensities of the
bands were quantiﬁed by densitometric analysis.
2.10. Statistical analysis
Histopathological scoring data were analyzed by the Krus-
kaleWallis test to determine the possible statistically signiﬁcant
differences among the groups and the ManneWhitney U-test was
used to test the differences between two groups. The other data
were analyzed using by one-way analysis of variance with the
StudenteNewmaneKeuls test. A value of P < 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. General observation and liver index
Bile duct ligation results in severe liver damage and deaths were
observed in all groups except control group. During the course of
experiment, 3 rats died in model group and 1e3 rats died in other
treated group. There was no statistical difference in survival be-
tween treated groups. Bile duct ligated animals in model group
gradually lost body weight after BDL. CA or Sil treatment signiﬁ-
cantly reduced this weight loss. As shown in Fig. 1, the liver index in
the model group increased highly compared to control group
(2.1 ± 0.09 vs. 4.5 ± 0.23, P < 0.001), which suggested that BDL
caused liver swelling. Compared to the model group, rats treated
with the dose 75 mg/kg and 150 mg/kg of CA signiﬁcantly deceased
the liver index (3.1 ± 0.16, 3.0 ± 0.11, P < 0.01, P < 0.01), which
shown that CA can ameliorate the swelling induced by BDL.
3.2. Blood biochemistry
Ligation of the common bile duct caused substantial hepato-
cellular injury, as indicated by a more than 31.5-fold, 4.7-fold andFig. 1. Effect of chlorogenic acid (CA) on liver index of BDL-rats. Data were expressed as
mean ± SD (n ¼ 9). Liver index: liver weight (g)/body weight (g) 100%. ###P < 0.001
compared with control group, **P < 0.01 compared with model group.6.1-fold increase in ALT, AST and ALP, respectively (Fig. 2A,B,F). Also,
BDL signiﬁcantly elevated TBIL, DBIL and TBA levels compared with
sham-treated animals, suggesting that signiﬁcant cholestasis was
induced in this model (Fig. 2C,D,E). As shown in Fig. 2, adminis-
tration of different dose of CA, especially 150 mg/kg, considerably
suppressed the release of ALT, AST and ALP from the liver by 84.1%,
76.4% and 51.6%, respectively, compared with model group. TBIL,
DBIL and TBA levels in rats treated with CA (75 mg/kg and 150 mg/
kg) after BDL were signiﬁcantly decreased than those in model
animals.3.3. Effect of CA on liver histopathologic changes
The liver histological changes were observed by HE staining as
shown in Fig. 3. The structure of the hepatic lobules in model group
was in disarray with the inﬁltration of many periportal inﬂamma-
tory cells. The hepatic plate was dissociated and hepatocytes were
swelling or lytic necrosis. Massive or sub massive necrosis of the
regenerated nodules was observed in some areas. However, liver
histology was signiﬁcantly improved in rats of CA treatment
groups, especially those in CA 75 mg/kg and 150 mg/kg. There was
an obvious decrease in inﬂammatory cell inﬁltration, and well-
arranged hepatic cords and the alleviation of hepatocyte swelling
was observed.3.4. Effect of CA on liver ﬁbrosis
BDL-induced liver ﬁbrosis was evidenced by ﬁber extension and
collagen accumulation, as visualized by increased staining intensity
with Masson's trichrome. As shown in Fig. 4, the development of
hepatic ﬁbrosis in the CA-treated groups as compared with the
model group was inhibited in the pericentral region, and occurred
mainly in the periportal region. There was a small degree of
bridging ﬁbrosis in the CA-treated groups. As shown in Table 2,
there were differences among the groups in terms of histopatho-
logical scoring according to the KruskaleWallis test (HC ¼ 28.8,
P < 0.005). Meanwhile, the liver ﬁbrosis scoring of CA (150 mg/kg)-
treated rats were signiﬁcantly lower than those in the model group
(P < 0.05).3.5. Inhibitory effect of CA on collagen synthesis and cytokine
expression
Total RNA for RT-PCR was isolated from rats livers of each group
used as a template for PCR ampliﬁcation. As shown in Fig. 5, the
levels of collagenmRNA in BDL-treated rats was signiﬁcantly higher
than those in the control group, and the collagen mRNA levels were
decreased in the rats treated with 75 mg/kg or 150 mg/kg CA.
Meanwhile, the expression of VEGF and TGF-b1 mRNA was
increased in the model group as compared with the control group.
The increased synthesis of VEGF and TGF-b1 mRNA in response to
BDL was suppressed markedly by 75 mg/kg or 150 mg/kg CA.3.6. Analysis of a-SMA expression by western blotting
To explore the mechanism underlying the protective effects of
CA against bile duct ligation induced liver injury, we examined a-
SMA expression. As shown in Fig. 6, the level of a-SMA in themodel
group, as determined by western blotting, was increased signiﬁ-
cantly compared to that in the control group, but it was reduced
signiﬁcantly after the treatment with CA (75 mg/kg and 150 mg/
kg).
Fig. 2. Effect of chlorogenic acid (CA) on blood biochemistry. The serum levels of (A) ALT, (B) AST, (C) TBIL, (D) DBIL, (E) TBA, and (F) ALP were determined. Data were expressed as
mean ± SD (n ¼ 9). ##P < 0.01, ###P < 0.001 compared with control group, *P < 0.05, **P < 0.01, ***P < 0.001 compared with model group.
Fig. 3. Histological images of rat livers stained with hematoxylin and eosin staining. Representative micrographs: 100 magniﬁcation.
D. Wu et al. / Journal of Pharmacological Sciences 129 (2015) 177e1821804. Discussion
The current study showed that CA could attenuate BDL-induced
liver injury, and suggested a beneﬁcial effect to protect liver from
ﬁbrosis. CA treatment improved liver function in term of serumALT,
AST, ALP, TBIL, DBIL and TBA on BDL-induced liver injury rats.Moreover, CA may inhibit the expression of a-SMA, collagen I and
collagen III, and decrease the secretion of TGF-b1 and VEGF. Taken
together, our results suggested that CA may have protective effect
against liver injury in rat model.
Rats subjected to bile duct ligation cause the retention of biliary
constituents and high biliary pressure caused hepatocellular injury
Fig. 4. Histological images of rat livers stained with Masson's trichrome. Representative micrographs: 100 magniﬁcation.
Table 2
Scoring of histopathological changes of liver.
Group Dose
(mg/kg)
Score of hepatic ﬁbrosis Mean rank
0 1 2 3 4
Control e 9 0 0 0 0 5
Model e 0 0 2 3 4 38.6a
CA-L 37.5 0 0 2 4 3 37.1
CA-M 75 0 0 3 5 1 32.3
CA-H 150 0 2 3 2 2 25.2b
Sil 50 0 1 4 2 2 26.9b
Each group consists of 9 rats and ﬁgures represent number of rat per grade.
a P < 0.001 compared with control group.
b P < 0.05 compared with model group.
Fig. 5. Effects of chlorogenic acid (CA) on collagen I, collagen III, TGF-b1, and VEGF
mRNA in the liver of BDL rats. (A) Representative RT-PCR of collagen I, collagen III, TGF-
b1 and VEGF. (B) Quantiﬁcation of the intensities of collagen I, collagen III, TGF-b1 and
VEGF. ##P < 0.01 compared with the control group; *P < 0.05 compared with the
model group.
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as ALT, AST and ALP were all increased in BDL treated rats. The liver
pathological changes observed by HE staining indicated that he-
patic lobules, hepatic plates and hepatocytes were abnormal in BDL
rats. However, the serum factors in CA treated rats were decreased,
especially in 75 and 150 mg/kg. Meanwhile, there was an obvious
decrease in inﬂammatory cell inﬁltration, and well-arranged he-
patic cords and the alleviation of hepatocyte swelling in CA treated
rats. These observations suggested that CA exerts anti-
inﬂammatory effect, which was consistent with previous study
results that CA reduces liver inﬂammation in CCl4-induced liver
injury in rats (21).
Hepatic ﬁbrosis, characterized by an increased production and
deposition of extracellular matrix component accompanies most
chronic liver disorders (22). In our study, collagen accumulation
was observed by Masson's trichrome in BDL rats after 3 weeks of
operation. Activated HSCs undergo phenotypic transformation,
which includes increased proliferation and contractility together
with the appearance of a-SMA ﬁlaments (23) and the accumulation
of ECM including type I and III collagen (24). In the current study, as
compared to the control group, the level of a-SMAwas increased in
BDL rats, but the increasing expression level was decreased by CA
treatment. The levels of collagen I and collagen III mRNA in the BDL
group was higher than those in the CA-treated group. This might
suggest that the inhibition of HSCs activation contributes to thedecreased production of collagen in CA treated rats. Previous
studies showed that TGF-b1 is involved in the excessive production
of ECM components and hepatic ﬁbrosis (25), and VEGF may
contribute to the development of liver ﬁbrosis by inducing the
proliferation of HSCs (26). In this study, we found that both of TGF-
Fig. 6. Effects of chlorogenic acid (CA) on a-SMA protein in the liver of BDL rats. (A)
Representative western blots of a-SMA (B) Quantiﬁcation of the intensities of a-SMA.
###P < 0.001 compared with control group; **P < 0.01 compared with model group.
D. Wu et al. / Journal of Pharmacological Sciences 129 (2015) 177e182182b1 and VEGF mRNA were decreased in rats treated with CA.
Therefore, it is likely that inhibition of the expression of TGF-b1 and
VEGF by CA plays a major role in the down-regulation of collagen
production.
In summary, all these results suggested that CA may protect
against liver injury caused by BDL. Although the mechanism was
not entirely clear, the present study revealed that the inhibitory
effect of CA on liver injury was associated with its ability to inhibit
the production of TGF-b1, VEGF and a-SMA. Therefore, our study
suggested that CA may be a potential drug for treating cholestasis-
related liver injury.
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